V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213144 | 20079642 | 1.73 | 102 | 03 | 2016-09-21 | 2016-09-21 | LANREOTIDE | null | N | LANREOTIDE | 101511701 |
| 20213145 | 20079643 | 1.97 | null | Palliative (P) | 2020-04-03 | 2020-04-03 | LANREOTIDE | 02 | N | LANREOTIDE | 101550726 |
| 20213146 | 20079644 | 1.69 | 71.6 | Palliative (P) | 2019-05-13 | 2019-05-16 | GO2 TRIAL | 1 | N | TRIAL | 101671803 |
| 20213148 | 20079645 | 1.71 | 64 | Adjuvant (A) | 2017-02-12 | 2017-03-12 | TCX | 02 | N | IMATINIB | 101056893 |
| 20213150 | 20079646 | 1.7 | 90.4 | Palliative (P) | null | null | HCX | 02 | N | TRIAL | 100243840 |
| 20213151 | 20079647 | 1.65 | 63.2 | Palliative (P) | 2021-05-17 | 2021-05-25 | Trial Unspecified | 01 | N | TRIAL | 101360972 |
| 20213153 | 20079648 | 1.68 | 76.3 | Palliative (P) | 2016-04-07 | 2016-04-21 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100889180 |
| 20213154 | 20079649 | 0 | 76.3 | Disease modification (D) | 2018-06-27 | 2018-07-18 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101235255 |
| 20213155 | 20079650 | 1.77 | 92.4 | 03 | 2017-08-14 | 2017-08-14 | Imatinib 600mg | 02 | N | IMATINIB | 101450435 |
| 20213156 | 20079651 | 1.61 | 75.4 | Curative (C) | null | 2017-11-26 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100388992 |
| 20213158 | 20079652 | 1.59 | 55.9 | Curative (C) | 2016-02-13 | 2016-02-23 | Fluorouracil+Mitomycin+RT (Anal Ca) | 2 | Y | FLUOROURACIL + MITOMYCIN + RT | 101325699 |
| 20213159 | 20079653 | 1.58 | 116.3 | Palliative (P) | 2019-04-01 | 2019-04-06 | HCX (Cape + Cisp + Tras) - Load | 02 | N | TRIAL | 100026717 |
| 20213160 | 20079654 | 1.76 | 72.5 | Palliative (P) | 2017-01-03 | 2017-02-01 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100933067 |
| 20213161 | 20079655 | 1.8 | 92.3 | Curative (C) | 2017-01-07 | 2017-01-20 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100665035 |
| 20213162 | 20079656 | 1.63 | 73.2 | Palliative (P) | 2016-09-20 | 2016-09-20 | LANREOTIDE | 02 | N | LANREOTIDE | 101030204 |
| 20213163 | 20079657 | 1.74 | 51 | Curative (C) | 2017-03-11 | 2017-03-12 | FLUOROURACIL + MITOMYCIN + RT | null | N | FLUOROURACIL + MITOMYCIN + RT | 101153943 |
| 20213164 | 20079658 | 1.73 | 104.9 | Palliative (P) | 2018-10-23 | 2018-10-23 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101637540 |
| 20213165 | 20079659 | 1.78 | 73.6 | Palliative (P) | 2019-02-17 | 2019-02-26 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101449326 |
| 20213169 | 20079662 | 1.62 | 0 | Palliative (P) | null | 2016-07-21 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100958637 |
| 20213170 | 20079663 | 1.55 | null | Curative (C) | 2018-07-09 | 2018-07-16 | Fluorouracil+Mitomycin+RT (Bladder) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100163567 |
| 20213172 | 20079665 | 1.62 | 51.5 | Disease modification (D) | 2017-06-14 | 2017-07-16 | HCX (Cape + Cisp + Tras) - Main | 02 | N | LANREOTIDE | 100022680 |
| 20213176 | 20079666 | 1.72 | 60.1 | Neo-adjuvant (N) | 2016-12-22 | 2016-12-30 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100619593 |
| 20213177 | 20079667 | 1.7 | 83 | Curative (C) | 2016-10-08 | 2016-10-15 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100073072 |
| 20213179 | 20079668 | 1.45 | 68.85 | Palliative (P) | 2016-06-27 | 2016-07-05 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100964980 |
| 20213180 | 20079669 | 1.8 | 92 | Curative (C) | 2019-10-27 | 2019-11-08 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100101736 |
| 20213182 | 20079670 | 1.58 | 99.3 | Curative (C) | 2018-04-30 | 2018-05-08 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101290203 |
| 20213184 | 20079671 | 1.67 | 70.7 | Palliative (P) | 2017-09-07 | 2017-09-12 | Trial Unspecified | Y | Y | TRIAL | 100047572 |
| 20213185 | 20079672 | 1.6 | 49 | null | 2019-03-23 | 2019-03-29 | Trial Unspecified | 01 | N | TRIAL | 100422710 |
| 20213186 | 20079673 | 1.71 | 92.8 | Palliative (P) | 2017-09-23 | 2017-09-24 | Cetuximab + FOLFIRI cycle1 | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100792760 |
| 20213187 | 20079674 | null | 89 | null | 2021-02-26 | 2021-02-26 | HCX (Cape + Cisp + Tras) - Load | 02 | N | LANREOTIDE | 101608967 |
| 20213189 | 20079675 | 1.68 | 65.3 | Palliative (P) | 2018-12-28 | 2019-01-05 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100756211 |
| 20213190 | 20079676 | 1.68 | 89 | Curative (C) | null | 2016-11-10 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101195309 |
| 20213191 | 20079677 | 0 | 132 | null | 2016-12-06 | 2016-12-26 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 101484197 |
| 20213193 | 20079678 | 1.62 | 58.2 | Palliative (P) | 2016-11-25 | 2016-11-29 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100619358 |
| 20213194 | 20079679 | 1.8 | 87 | Palliative (P) | 2018-02-18 | 2018-03-15 | Cetuximab + FLUOROURACIL + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100917451 |
| 20213196 | 20079680 | 1.85 | 83.35 | Curative (C) | 2017-05-24 | 2017-06-03 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101858089 |
| 20213198 | 20079681 | 1.71 | 0 | Palliative (P) | 2017-04-29 | 2017-05-14 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101654640 |
| 20213199 | 20079682 | 1.68 | 75 | Disease modification (D) | 2018-06-08 | 2018-06-08 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101744630 |
| 20213200 | 20079683 | 1.69 | 61.7 | Curative (C) | 2017-10-01 | 2017-10-20 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101419616 |
| 20213201 | 20079684 | 1.76 | 78.5 | Neo-adjuvant (N) | 2018-04-13 | 2018-05-23 | Fluorouracil+Mitomycin+RT (Bladder) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101169661 |
| 20213202 | 20079685 | 1.66 | 87 | Palliative (P) | 2019-05-22 | 2019-06-06 | Trial Unspecified | 01 | N | TRIAL | 101755214 |
| 20213203 | 20079686 | 1.62 | 74.25 | Palliative (P) | 2018-05-03 | 2018-06-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100788053 |
| 20213207 | 20079689 | 1.72 | 76.1 | Curative (C) | 2019-01-16 | 2019-01-16 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101425691 |
| 20213208 | 20079690 | 1.9 | 68.3 | Palliative (P) | 2018-03-18 | 2018-04-01 | IMATINIB | 02 | N | IMATINIB | 100552216 |
| 20213209 | 20079691 | 0 | 84.3 | Palliative (P) | 2019-05-24 | 2019-06-14 | Trial Unspecified | N | null | TRIAL | 100688257 |
| 20213210 | 20079692 | 1.74 | 79.85 | Curative (C) | 2017-05-27 | 2017-05-30 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 101254155 |
| 20213211 | 20079693 | 1.7 | 56.4 | Curative (C) | 2019-07-05 | 2019-08-13 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100129926 |
| 20213212 | 20079694 | 1.64 | 87.8 | Palliative (P) | 2017-07-10 | 2017-07-26 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101171606 |
| 20213213 | 20079695 | 1.5 | 84.2 | Palliative (P) | 2019-10-20 | 2019-10-20 | Trial Unspecified | 01 | N | TRIAL | 101058242 |
| 20213214 | 20079696 | 1.71 | 81 | Palliative (P) | 2017-08-30 | 2017-09-03 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100326496 |